Page 9 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Systemic therapies:

Abiraterone acetate

• Abiraterone acetate (1000 mg daily) with prednisone (5 mg daily) plus ADT

is an option for patients with at least two of three of:

– Gleason score of ≥8, presence of three or more lesions on bone scan, or
presence of measurable visceral metastasis (Level 1, Strong recommendation)

• Abiraterone acetate (1000 mg daily) with prednisone (5 mg daily) plus ADT
may be considered for patients with low-volume mCNPC (Level 3, Weak

recommendation)

ADT: androgen-deprivation therapy; mCNPC: metastatic castration-naive prostate cancer